Company Overview
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Why Investors Should Care
Revenue has grown at a 57.5% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.32.
Recent Developments
- Dec 2025 Revenue of $9.77M (+17.3% YoY); net profit $-109.00M.
- Trailing 12 Months Year-on-year growth — revenue +17.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 57.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 57.49% |
| 1 Year: | 17.28% |
Stock Price Performance
| 1 Year: | +115.91% |
| 6 Months: | +14.46% |
| 3 Months: | +28.96% |
| 1 Month: | +2.15% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 57.5% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TSHA Taysha Gene Therapies, Inc. R2K | 5.70 | -15.00 | $1.64B | 0.00% | -34.88% | -97.28% | 57.49% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 4.71M | 2.40M | 4.75M | 3.41M | 1.11M | 1.79M | 2.30M | 1.99M | 0 | 0 |
| Operating Income | -1.11M | -5.58M | -4.01M | -15.04M | -32.09M | -40.77M | -50.68M | -49.65M | -33.37M | -25.46M | -16.56M | -23.38M | -16.25M | -24.33M | -21.30M | -25.90M | -21.42M | -26.75M | -34.02M | -43.49M |
| Net Income | -1.11M | -5.43M | -21.22M | -15.04M | -32.02M | -40.93M | -51.19M | -50.32M | -34.09M | -26.53M | -17.62M | -24.60M | -117.09M | -24.06M | -20.93M | -25.52M | -21.53M | -26.88M | -32.73M | -42.41M |
| Diluted EPS | - | - | - | - | - | -1.09 | -1.35 | -1.32 | -0.85 | -0.65 | -0.28 | -0.38 | -0.93 | -0.10 | -0.09 | -0.10 | -0.08 | -0.09 | -0.09 | -0.12 |
| R&D Expense | 987.00K | 5.51M | 3.06M | 11.06M | 23.85M | 30.64M | 39.53M | 38.18M | 23.51M | 16.77M | 12.51M | 19.79M | 11.79M | 20.66M | 15.07M | 14.95M | 15.56M | 20.14M | 25.75M | 33.81M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 2.50M | 15.45M | 8.33M | 9.77M |
| Operating Income | -43.00M | -173.27M | -162.45M | -72.44M | -91.46M | -110.50M |
| Net Income | -60.01M | -174.52M | -166.01M | -111.57M | -89.30M | -109.00M |
| Diluted EPS | - | -4.64 | -3.78 | -0.96 | -0.36 | -0.34 |
| R&D Expense | 31.89M | 131.94M | 91.17M | 56.78M | 66.00M | 86.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Sep 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 15.00K | 258.88M | 213.96M | 126.28M | 172.73M | 160.36M | 343.32M |
| Total Equity | 0 | -135.00K | 251.30M | 95.38M | 949.00K | 74.94M | 71.53M | 246.94M |
| Cash & Equivalents | - | - | 251.25M | 149.10M | 87.88M | 143.94M | 139.04M | 319.77M |
| Long Term Debt | - | - | - | 37.19M | 37.97M | 40.51M | 43.94M | 50.11M |
| Total Liabilities | - | 150.00K | 7.58M | 118.57M | 125.33M | 97.79M | 88.84M | 96.38M |
| Current Liabilities | - | 150.00K | 7.13M | 51.75M | 62.79M | 36.76M | 26.23M | 26.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -30.73M | -117.04M | -88.39M | -73.02M | -81.22M | -93.09M |
| Investing Cash Flow | -9.08M | -21.55M | -24.93M | -7.35M | -363.00K | -604.00K |
| Financing Cash Flow | 291.06M | 39.08M | 52.10M | 136.39M | 76.68M | 274.59M |
| Capital Expenditure | -82.00K | -15.30M | -20.62M | -3.87M | -374.00K | -738.00K |
| Free Cash Flow | -30.81M | -132.35M | -109.01M | -76.89M | -81.60M | -93.83M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | -6,492.7% | -468.8% | -1,097.6% | -1,130.6% |
| Net Margin % | - | - | -6,635.3% | -722.1% | -1,071.6% | -1,115.3% |
| ROE % | -23.9% | -183.0% | -17,493.6% | -148.9% | -124.8% | -44.1% |
| ROCE % | -17.1% | -106.8% | -255.9% | -53.3% | -68.2% | -34.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 8.20% | 23.56M | $153.35M |
| 2 | Goldman Sachs Group Inc | 7.78% | 22.37M | $145.63M |
| 3 | Avoro Capital Advisors LLC | 7.55% | 21.70M | $141.27M |
| 4 | Blackrock Inc. | 6.39% | 18.37M | $119.56M |
| 5 | Vestal Point Capital, LP | 6.26% | 18.00M | $117.18M |
| 6 | Morgan Stanley | 6.25% | 17.97M | $116.95M |
| 7 | FMR, LLC | 4.98% | 14.32M | $93.23M |
| 8 | RTW Investments LP | 4.76% | 13.68M | $89.06M |
| 9 | State Street Corporation | 3.90% | 11.21M | $72.97M |
| 10 | Vanguard Capital Management LLC | 3.56% | 10.23M | $66.61M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TSHA
$TSHA stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNc1JNRzQ2Y0x2UWJzM05aODVoWmpKUnBXeGVOd1A1ZE9pSVB2eXQxRGJycTFmSW1seEFBanZLOXpFQVFFd2hLMjFFYUZQMTd3MGhNN3ViMVIwZFQxM0VYWklGME1uSm03blpiekRtMkVsQTFfbEY1Mjh4RGJJblVyZWtGSGZkb0YxMko3bT…
Taysha Gene Therapies (TSHA) investor files to sell 200,000 shares via Jefferies - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOTTc4VUw5MUlSUVVCWm1hclA0bzJmeWlpODlKTmE0SFkxd0x2N2tNbkRLYVZCUEgwXzVTWE1nSEdLb3JTc1Z1VWIybVNXZXVoOWFxYVM2T3Z0ZXBkckxoMXZwZ3o3ZkwxV2dKM0toa19zZGxMNzdJcHFwMkFSYnZVbWlLV0VqYlNBY2xpWU…
Taysha Gene Therapies (TSHA) Experiences Significant Decline - GuruFocus
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPdGtWV0I3Vnp2bGl3Z0lYelIxX05FdWJsLXZ2Tnp4eF9XOGQ2OFVmNU1taU5yX0Nhd2syNWU3aG5zLV9lRkRHcUUyYzZHX3VaYll6eXFuMV9GQjZHbVRyeDRBRTVZY2tfbGZYVnEzWGRKX21PU3VZcHVxdXBqczBheFVqSUFHVEJ1TG1CY2…
Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNLTRmeFRWaDB1ckdoZFQ0bVh4SlMzMUFKX1BvMWFmOG0zWFI2T1lXazZaWGY3LWlMVy1KeDlpRXVrMXJQZHdMSWRBb1lsVGJoMEtaMjdMM3dhZkdEeklkenJoVG9LNnRncVhBY3FELTJNZ2k2RWQ2TERnTWhObzBWTGhhbmFvek1zd0hwN3…
Insider Sale: President and Head of R&D of $TSHA Sells 200,000 Shares - Moomoo
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOSVN2RUJZaFdRalA3Y3NNemNJZlppU2lnX3ZXWk50ZHF1TExqZktwTkRwMEZxT2YwUXZja3VYQVc3d1NMWXp1Ry1sdFhIVHRmczVCYlo0WjB3anhTSDRLREtGWDhpMlNFNHpDWHFoVkNNaFVWajc1NU5FcUF1WURCeG9hTGtELTVzUDlCbE…
Taysha Gene Therapies president sells $1.25m in stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPaE1QOXZCWk1WRHZ4WFBCN1pQNkdqSDhMR1VnZkVlYjFYNjAxdlV4Q1NvRXo0VkhtQm53Y1NBVkhIbnpaV1pIZ0dVOHRTRDBDMmRMNVRqSTJyV3E2WXdiR2p2aTRucHJkNGFKWGI5d1FOamJ1dDVUZWZBR0lJX3Q3YXlYZmJwbG9QU1dlR1…
TSHA — Frequently Asked Questions
What is the current share price of Taysha Gene Therapies, Inc. (TSHA)?
As of 2026-07-14 21:23 PDT, Taysha Gene Therapies, Inc. (TSHA) trades at $5.70 on NasdaqGS. Its 52-week range is $2.51 to $6.98.
What is the market capitalisation of TSHA?
Taysha Gene Therapies, Inc. (TSHA) has a market capitalisation of $1.64B on NasdaqGS.
What is the P/E ratio of TSHA?
TSHA trades at a trailing price-to-earnings (P/E) ratio of -15.00. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 7.74.
What is the return on equity (ROE) of TSHA?
TSHA has a return on equity (ROE) of -97.28%. Its return on capital employed (ROCE) is -34.88%.
Is TSHA a good stock to buy?
This page provides a data-driven analysis of Taysha Gene Therapies, Inc. (TSHA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.